Skip to main content

Table 1 Demographic and clinical data

From: Potential diagnostic markers of olanzapine efficiency for acute psychosis: a focus on peripheral biogenic amines

Demographic and clinical data1 Patient group treated with haloperidol (n = 30) Patient group treated with olanzapine (n = 30)
Daily dose (Range) (mg/day) 19.8 ± 5.6 (2.5–30) 18.5 ± 3.9 (10–20)
Age (Range) (yrs) 29.4 ± 8.1 (19–53) 26.4 ± 6.19 (18–43)
BMI2 (Range) (kg/m2) 23.4 ± 3.76 (17–31.7) 22.6 ± 4.1 (16.2–35.3)
Acute psychosis:   
Paranoid schizophrenia 21 (70%) 14 (46.7%)
Acute polymorphic psychotic disorder with symptoms of schizophrenia 9 (30%) 10 (33.3%)
Simple type of schizophrenia 1 (3.3%)
Another type of schizophrenia 1 (3.3%)
Acute polymorphic psychotic disorder with symptoms of schizophrenia 2 (6.7%)
Acute schizophrenic disorder 2 (6.7%)
  1. 1All values are reported as the means ± standard deviation
  2. 2BMI – Body mass index was calculated as weight in kilograms divided by height squared in metres